Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection. As TG modulates neurotransmitter metabolism affecting serotonin and dopamine we hypothesize that this chronic persistent infection might play a role for depressive and psychotic symptomatology. Therefore, on the basis of an ex juvantibus approach, specific anti TG medication might further improve psychiatric symptomatology in affected patients. This is investigated in a double-blind, placebo-controlled, randomized treatment trial.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zentrum für Integrative Psychiatrie
• Collaborator: Stanley Medical Research Institute
• Treatments: Folic Acid; Leucovorin; Levoleucovorin; Pyrimethamine

Criteria

Inclusion Criteria:

• Schizophrenia or Major Depression

• Both genders

• Adult

• Patients are able to give informed consent

Exclusion Criteria:

• Additional diagnosis of substance abuse/dependency

• Continuous treatment with medication not compatible with study medication

• Medical status not compatible with study medication

• Any condition that increases study risk considerably

• Pregnancy, nursing